ATAI — ATAI Life Sciences NV Balance Sheet
0.000.00%
Last trade - 00:00
- $320.43m
- $160.40m
- $0.31m
- 19
- 15
- 73
- 28
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 30.1 | 97.2 | 362 | 273 | 179 |
Net Total Receivables | 8.7 | 1.29 | 6.32 | 10.3 | 4.08 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 39.1 | 99.5 | 375 | 287 | 186 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.021 | 0.071 | 0.149 | 0.928 | 2.2 |
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 62.1 | 112 | 414 | 305 | 293 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1.61 | 12.3 | 20.9 | 19.9 | 20.1 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 3.37 | 20.7 | 37.3 | 44.7 | 50.5 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 58.8 | 90.8 | 377 | 261 | 243 |
Total Liabilities & Shareholders' Equity | 62.1 | 112 | 414 | 305 | 293 |
Total Common Shares Outstanding |